
Minerva Neurosciences, a US-based biopharmaceutical firm, develops therapies for CNS and neuropsychiatric diseases.
Minerva Neurosciences, founded in Waltham, United States, is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for central nervous system (CNS) and neuropsychiatric diseases. The company's core mission is to improve the lives of patients suffering from conditions such as schizophrenia and Parkinson's disease. Minerva's product pipeline includes promising drug candidates like Roluperidone (MIN-101), aimed at addressing unmet medical needs in these therapeutic areas.
Notable figures associated with Minerva Neurosciences include its experienced leadership team and board of directors, who bring extensive expertise in biotechnology and pharmaceuticals. The company has garnered attention from investors and the medical community for its innovative approach to treating CNS disorders. Key achievements include advancing their drug candidates through various stages of clinical trials, demonstrating potential efficacy and safety. Minerva's impact lies in its commitment to pioneering new treatments that could significantly enhance patient outcomes in neuropsychiatric care.

Neurana Pharmaceuticals
neuranapharma.com

Minerva Biotechnologies
minervabio.com

Intellect Neurosciences

Reservoir Neuroscience
reservoirneuro.com

Neuraly
neuralymed.com

MentiNova

Psy Therapeutics
psythx.com

Neurolixis
neurolixis.com

Neurovia

NeuroTherapia
neurotherapia.com

Supernus Pharmaceuticals
supernus.com

Marinus Pharmaceuticals
marinuspharma.com

NeuroTherapeutics Pharma

NeurOp

Cerevance
cerevance.com
Companies similar to Minerva Neurosciences include Neurana Pharmaceuticals, Minerva Biotechnologies, Intellect Neurosciences and Reservoir Neuroscience.
Minerva Neurosciences was founded in 2007.
Minerva Neurosciences' headquarters is located in Waltham, MA, US.
Minerva Neurosciences' most recent funding round was for $88k (USD) in December 2019.
As of Dec 18, 2019, Minerva Neurosciences has raised a total of $51.3M (USD).
Minerva Neurosciences has 9 employees as of Feb 6, 2024.